Cargando…

Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy

This study aimed to identify factors that predict prognosis after radiotherapy for brain metastases (BMs) from small-cell lung cancer (SCLC). This study retrospectively evaluated 48 consecutive patients who underwent whole-brain radiotherapy (WBRT) for BMs from SCLC between February 2008 and Decembe...

Descripción completa

Detalles Bibliográficos
Autores principales: Anami, Shimpei, Doi, Hiroshi, Nakamatsu, Kiyoshi, Uehara, Takuya, Wada, Yutaro, Fukuda, Kohei, Inada, Masahiro, Ishikawa, Kazuki, Kanamori, Shuichi, Nishimura, Yasumasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430245/
https://www.ncbi.nlm.nih.gov/pubmed/30576550
http://dx.doi.org/10.1093/jrr/rry107
_version_ 1783405746296193024
author Anami, Shimpei
Doi, Hiroshi
Nakamatsu, Kiyoshi
Uehara, Takuya
Wada, Yutaro
Fukuda, Kohei
Inada, Masahiro
Ishikawa, Kazuki
Kanamori, Shuichi
Nishimura, Yasumasa
author_facet Anami, Shimpei
Doi, Hiroshi
Nakamatsu, Kiyoshi
Uehara, Takuya
Wada, Yutaro
Fukuda, Kohei
Inada, Masahiro
Ishikawa, Kazuki
Kanamori, Shuichi
Nishimura, Yasumasa
author_sort Anami, Shimpei
collection PubMed
description This study aimed to identify factors that predict prognosis after radiotherapy for brain metastases (BMs) from small-cell lung cancer (SCLC). This study retrospectively evaluated 48 consecutive patients who underwent whole-brain radiotherapy (WBRT) for BMs from SCLC between February 2008 and December 2017. WBRT was delivered at a median dose of 30 Gy (range: 30–40 Gy) in 10 fractions (range: 10–16 fractions). Clinical factors were tested for associations with overall survival after WBRT. The median survival and 1-year overall survival rate after WBRT treatment were 232 days and 34.4%, respectively. Univariate analyses revealed that longer survival was associated with Eastern Cooperative Oncology Group performance status of 0–1, asymptomatic BMs, lactate dehydrogenase (LDH) in the normal range, Radiation Therapy Oncology Group–recursive partitioning analysis class 2, and a graded prognostic assessment score of ≥1.5 (P < 0.01, P < 0.01, P < 0.01, P < 0.01 and P < 0.05, respectively). In the multivariate analyses, longer survival was independently associated with asymptomatic BMs [hazard ratio for death (HR), 0.32; 95% confidence interval (CI), 0.12–0.79; P < 0.05] and LDH in the normal range (HR, 0.42; 95% CI, 0.21–0.83; P < 0.05). The presence of symptoms due to BMs and LDH values independently predicted prognosis after WBRT for BMs from SCLC. Elevated LDH may provide valuable information for identifying patients with BMs who could have poor survival outcomes.
format Online
Article
Text
id pubmed-6430245
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-64302452019-03-26 Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy Anami, Shimpei Doi, Hiroshi Nakamatsu, Kiyoshi Uehara, Takuya Wada, Yutaro Fukuda, Kohei Inada, Masahiro Ishikawa, Kazuki Kanamori, Shuichi Nishimura, Yasumasa J Radiat Res Regular Paper This study aimed to identify factors that predict prognosis after radiotherapy for brain metastases (BMs) from small-cell lung cancer (SCLC). This study retrospectively evaluated 48 consecutive patients who underwent whole-brain radiotherapy (WBRT) for BMs from SCLC between February 2008 and December 2017. WBRT was delivered at a median dose of 30 Gy (range: 30–40 Gy) in 10 fractions (range: 10–16 fractions). Clinical factors were tested for associations with overall survival after WBRT. The median survival and 1-year overall survival rate after WBRT treatment were 232 days and 34.4%, respectively. Univariate analyses revealed that longer survival was associated with Eastern Cooperative Oncology Group performance status of 0–1, asymptomatic BMs, lactate dehydrogenase (LDH) in the normal range, Radiation Therapy Oncology Group–recursive partitioning analysis class 2, and a graded prognostic assessment score of ≥1.5 (P < 0.01, P < 0.01, P < 0.01, P < 0.01 and P < 0.05, respectively). In the multivariate analyses, longer survival was independently associated with asymptomatic BMs [hazard ratio for death (HR), 0.32; 95% confidence interval (CI), 0.12–0.79; P < 0.05] and LDH in the normal range (HR, 0.42; 95% CI, 0.21–0.83; P < 0.05). The presence of symptoms due to BMs and LDH values independently predicted prognosis after WBRT for BMs from SCLC. Elevated LDH may provide valuable information for identifying patients with BMs who could have poor survival outcomes. Oxford University Press 2019-03 2018-12-20 /pmc/articles/PMC6430245/ /pubmed/30576550 http://dx.doi.org/10.1093/jrr/rry107 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial reuse, please contact journals.permissions@oup.com
spellingShingle Regular Paper
Anami, Shimpei
Doi, Hiroshi
Nakamatsu, Kiyoshi
Uehara, Takuya
Wada, Yutaro
Fukuda, Kohei
Inada, Masahiro
Ishikawa, Kazuki
Kanamori, Shuichi
Nishimura, Yasumasa
Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy
title Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy
title_full Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy
title_fullStr Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy
title_full_unstemmed Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy
title_short Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy
title_sort serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy
topic Regular Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430245/
https://www.ncbi.nlm.nih.gov/pubmed/30576550
http://dx.doi.org/10.1093/jrr/rry107
work_keys_str_mv AT anamishimpei serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT doihiroshi serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT nakamatsukiyoshi serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT ueharatakuya serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT wadayutaro serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT fukudakohei serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT inadamasahiro serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT ishikawakazuki serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT kanamorishuichi serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy
AT nishimurayasumasa serumlactatedehydrogenasepredictssurvivalinsmallcelllungcancerpatientswithbrainmetastasesthatweretreatedwithwholebrainradiotherapy